I agree that this site is using cookies. You can find further informations here.
X
Sibren van den Berg
25  results:
Search for persons X
?
1

Development of medicines for rare diseases and inborn error..:

Rosenberg, Noa ; Stolwijk, Nina N. ; van den Berg, Sibren...
Journal of Inherited Metabolic Disease.  46 (2023)  5 - p. 806-816 , 2023
Link: https://doi.org/10.1002/..
 
?
2

Access to medicines for rare diseases: A European regulator..:

Rosenberg, Noa ; van den Berg, Sibren ; Stolwijk, Nina N....
Frontiers in Pharmacology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
3

Modified Delphi procedure-based expert consensus on endpoin..:

Schoenmakers, Daphne H. ; Beerepoot, Shanice ; van den Berg, Sibren...
Orphanet Journal of Rare Diseases.  17 (2022)  1 - p. , 2022
Link: https://doi.org/10.1186/..
 
?
4

PP152 The Assessment Of The Price Of A Medicine: The Possib..:

Van Den Berg, Sibren ; Canoy, Marcel ; Timmers, Lonneke.
International Journal of Technology Assessment in Health Care.  38 (2022)  S1 - p. S89-S90 , 2022
Link: https://doi.org/10.1017/..
 
?
5

Author Reply:

van den Berg, Sibren ; de Visser, Saco J. ; Timmers, Lonneke.
Value in Health.  25 (2022)  1 - p. 158-159 , 2022
Link: https://doi.org/10.1016/..
 
?
6

Towards sustainability and affordability of expensive cell ..:

Thielen, Frederick W. ; Heine, Renaud J.S.D. ; Berg, Sibren van den..
Cytotherapy.  24 (2022)  12 - p. 1245-1258 , 2022
Link: https://doi.org/10.1016/..
 
?
7

Effectiveness and safety of mexiletine in patients at risk ..:

van der Ree, Martijn H ; van Dussen, Laura ; Rosenberg, Noa...
EP Europace.  24 (2022)  11 - p. 1809-1823 , 2022
Link: https://doi.org/10.1093/..
 
?
8

Cost-Based Price Calculation of Mexiletine for Nondystrophi..:

van den Berg, Sibren ; van der Wel, Vincent ; de Visser, Saco J....
Value in Health.  24 (2021)  7 - p. 925-929 , 2021
Link: https://doi.org/10.1016/..
 
?
9

Drug Repurposing for Rare Diseases: A Role for Academia:

van den Berg, Sibren ; de Visser, Saco ; Leufkens, Hubert G.M..
Frontiers in Pharmacology.  12 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
10

Registries for orphan drugs: generating evidence or marketi..:

Hollak, Carla E. M. ; Sirrs, Sandra ; van den Berg, Sibren...
Orphanet Journal of Rare Diseases.  15 (2020)  1 - p. , 2020
Link: https://doi.org/10.1186/..
 
?
11

Access to medicines for rare diseases: A European regulator..:

Noa Rosenberg ; Sibren van den Berg ; Nina N. Stolwijk...
https://www.frontiersin.org/articles/10.3389/fphar.2023.1142351/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
12

Table1_Access to medicines for rare diseases: A European re..:

Noa Rosenberg ; Sibren van den Berg ; Nina N. Stolwijk...
doi:10.3389/fphar.2023.1142351.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
13

Modified Delphi procedure-based expert consensus on endpoin..:

Daphne H. Schoenmakers ; Shanice Beerepoot ; Sibren van den Berg...
https://doi.org/10.1186/s13023-022-02189-w.  , 2022
Link: https://doi.org/10.1186/..
 
?
14

Drug Repurposing for Rare Diseases: A Role for Academia:

Sibren van den Berg ; Saco de Visser ; Hubert G.M. Leufkens.
https://www.frontiersin.org/articles/10.3389/fphar.2021.746987/full.  , 2021
Link: https://doi.org/10.3389/..
 
?
15

Registries for orphan drugs: generating evidence or marketi..:

Carla E. M. Hollak ; Sandra Sirrs ; Sibren van den Berg...
http://link.springer.com/article/10.1186/s13023-020-01519-0.  , 2020
Link: https://doi.org/10.1186/..
 
1-15